Louisiana State Employees Retirement System Decreases Stake in DaVita Inc. (NYSE:DVA)

Louisiana State Employees Retirement System lessened its stake in shares of DaVita Inc. (NYSE:DVA) by 6.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,900 shares of the company’s stock after selling 200 shares during the period. Louisiana State Employees Retirement System’s holdings in DaVita were worth $402,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Private Advisory Group LLC purchased a new stake in shares of DaVita during the second quarter valued at $823,000. Hennessy Advisors Inc. acquired a new position in shares of DaVita in the second quarter valued at about $8,439,000. Atria Wealth Solutions Inc. raised its stake in shares of DaVita by 26.7% in the second quarter. Atria Wealth Solutions Inc. now owns 6,068 shares of the company’s stock worth $841,000 after purchasing an additional 1,279 shares during the last quarter. First Horizon Advisors Inc. lifted its holdings in shares of DaVita by 56.3% during the second quarter. First Horizon Advisors Inc. now owns 1,632 shares of the company’s stock worth $226,000 after purchasing an additional 588 shares during the period. Finally, Nisa Investment Advisors LLC boosted its position in DaVita by 26.8% in the second quarter. Nisa Investment Advisors LLC now owns 36,694 shares of the company’s stock valued at $5,085,000 after buying an additional 7,752 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on DVA. TD Cowen lifted their price objective on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. StockNews.com lowered shares of DaVita from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 8th. UBS Group lifted their price objective on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Barclays upped their target price on DaVita from $133.00 to $150.00 and gave the stock an “equal weight” rating in a research note on Monday, May 6th. Finally, Truist Financial boosted their price target on DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a report on Tuesday, August 20th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, DaVita has an average rating of “Hold” and a consensus target price of $157.00.

DaVita Price Performance

Shares of DaVita stock opened at $150.92 on Friday. The firm has a market cap of $13.24 billion, a PE ratio of 17.15, a P/E/G ratio of 0.89 and a beta of 0.87. The business has a 50-day moving average price of $142.50 and a 200 day moving average price of $137.82. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. DaVita Inc. has a twelve month low of $71.51 and a twelve month high of $156.44.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.47 by $0.12. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The business had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.15 billion. During the same period in the previous year, the business earned $2.08 earnings per share. The business’s revenue was up 6.2% compared to the same quarter last year. Sell-side analysts predict that DaVita Inc. will post 9.99 earnings per share for the current fiscal year.

Insider Transactions at DaVita

In other news, CEO Javier Rodriguez sold 32,176 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the completion of the sale, the chief executive officer now owns 905,659 shares of the company’s stock, valued at $141,219,407.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other DaVita news, COO Michael David Staffieri sold 9,539 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $150.03, for a total value of $1,431,136.17. Following the transaction, the chief operating officer now directly owns 241,945 shares of the company’s stock, valued at approximately $36,299,008.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Javier Rodriguez sold 32,176 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $155.93, for a total value of $5,017,203.68. Following the completion of the sale, the chief executive officer now owns 905,659 shares of the company’s stock, valued at $141,219,407.87. The disclosure for this sale can be found here. Insiders have sold 113,601 shares of company stock valued at $17,525,449 over the last ninety days. Insiders own 2.00% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.